Author

M. Jost

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 3 Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 3 Research Focus:gene regulatory network inference· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Assay:proteomics· 2

Frequent Co-Authors

J. S. Weissman· 5 shared M. A. Horlbeck· 3 shared C. R. Liem· 2 shared M. E. Tanenbaum· 2 shared M. Kampmann· 2 shared A. Akhmanova· 1 shared A. Celli· 1 shared A. E. Prota· 1 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCell Biology

J. S. Weissman

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Comprehensive Interrogation of Synthetic Relationships in the Human DNA Damage Response

J. Fielden, S. M. Siegner, D. N. Gallagher, M. Schroeder, M. R. Dello Stritto, L. Kobel, M. Schlapansky, P. Cejka, M. Jost, J. E. Corn

The paper maps genetic interactions of DDR genes using CRISPRi screening, identifies key interactions with therapeutic potential, and provides insights into genome maintenance mechanisms.

bioRxiv · Aug 18, 2023Cell Biology

Genome-wide CRISPRi screening identifies OCIAD1 as a prohibitin client and regulatory determinant of mitochondrial Complex III assembly in human cells

M. Le Vasseur, J. R. Friedman, M. Jost, J. Xu, J. Yamada, M. Kampmann, M. A. Horlbeck, M. R. Salemi, B. S. Phinney, J. S. Weissman, J. Nunnari

bioRxiv · Feb 16, 2021Cell Biology

Selective Targeting of Ras Mutant Cancers via a New Small Molecule

B. Tolani, A. Celli, Y. Yao, Y. Z. Tan, R. Fetter, C. R. Liem, A. J. de Smith, T. Vasanthakumar, P. Bisignano, I. B. Seiple, J. L. Rubinstein, M. Jost, J. S. Weissman

This paper identifies 249C as a small molecule that selectively targets Ras-mutant cancers by inhibiting V-ATPase, disrupting lysosomal acidification and key survival pathways in Ras-driven tumors.

bioRxiv · Dec 23, 2020Cancer Biology

CRISPR-based functional genomics in human dendritic cells

M. Jost, A. N. Jacobson, J. A. Hussmann, G. Cirolia, M. Fischbach, J. S. Weissman

This study develops a CRISPR/Cas9 method for human dendritic cells, enabling efficient gene knockouts and revealing mechanisms of immune response tuning to microbiome lipopolysaccharides.

bioRxiv · Dec 22, 2020Immunology

High-content Imaging-based Pooled CRISPR Screens in Mammalian Cells

X. Yan, N. Stuurman, S. A. Ribeiro, M. E. Tanenbaum, M. A. Horlbeck, C. R. Liem, M. Jost, J. S. Weissman, R. Vale

The paper develops an imaging-based CRISPR screening method called optical enrichment to identify genes affecting nuclear size, identifying 14 hits from 6092 sgRNAs.

bioRxiv · Jun 30, 2020Cell Biology

Pharmaceutical-grade Rigosertib is a Microtubule-destabilizing Agent

M. Jost, Y. Chen, L. A. Gilbert, M. A. Horlbeck, L. Krenning, G. Menchon, A. Rai, M. Y. Cho, J. J. Stern, A. E. Prota, M. Kampmann, A. Akhmanova, M. O. Steinmetz, M. E. Tanenbaum, J. S. Weissman

This paper shows pharmaceutical-grade rigosertib, with high purity, causes microtubule destabilization in cells, confirming its mechanism of action against cancer cells.

bioRxiv · Jan 28, 2020Cancer Biology